Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study

All six non-Hodgkin lymphoma patients on Legend Biotech’s CAR T therapy responded to treatment—findings that could make the biotech an attractive takeover target, according to analysts at Oppenheimer.